From Russia (with love?) [RSABE / ABEL]

posted by PharmCat  – Russia, 2019-12-04 15:16 (1028 d 00:11 ago) – Posting: # 20924
Views: 5,441

Hello Helmut!

IMHO, main points:

1. Basic words. Review article.
2. ABEL/RSABE - all have TIE inflation.
3. Biggest inflation when CVintra = 25—30%.
4. EMA aproach better than FDA.

Conclusion:

When you are planning bioequivalence trial better look at EMA guidelines, rather than FDA. We know that all approaches have TIE inflation.

I think this is primarily a message to regulatory experts.

Complete thread:

UA Flag
Activity
 Admin contact
22,391 posts in 4,685 threads, 1,594 registered users;
online 15 (0 registered, 15 guests [including 3 identified bots]).
Forum time: Tuesday 16:27 CEST (Europe/Vienna)

Statistics. A sort of elementary form of mathematics which consists of
adding things together and occasionally squaring them.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5